Reviewer's report

**Title:** Safety and efficacy of Rituximab treatment for vasculitis in hepatitis B virus-associated Type II cryoglobulinemia: a case report

**Version:** 1  **Date:** 6 October 2011

**Reviewer:** agostino colli

Which of the following best describes what type of case report this is?: Other

If other, please specify:

possible management of a less common subtype of a rare disease

Has the case been reported coherently?: Yes

Is the case report authentic?: Yes

Is the case report ethical?: Yes

Is there any missing information that you think must be added before publication?: Yes

Is this case worth reporting?: Yes

Is the case report persuasive?: Yes

Does the case report have explanatory value?: Yes

Does the case report have diagnostic value?: No

Will the case report make a difference to clinical practice?: Yes

Is the anonymity of the patient protected?: Yes

**Comments to authors:**

Data on HBV viremia and treatment need to be more detailed.
What is HBV DNA level before starting immunosuppressive treatment.
Anyway no prophylaxis (with lamivudine) was started and this was an error that should be made explicit. Furthermore it is no data on clear how viremia course and when lamivudine and then entecavir were started.
These data are relevant for the interpretation of the report and the possible effect of antiviral treatment on the disease course.
Quality of written English: Acceptable

Declaration of competing interests:
‘I declare that I have no competing interests’